Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD), has announced it will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT. The webinar will feature founder, President and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs and upcoming milestones, including the fully enrolled pivotal Phase 3 AD trial, with top-line data and regulatory submissions expected in 2027.
The announcement comes at a critical juncture for Annovis as it advances buntanetap, an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company’s lead candidate, formerly known as posiphen, has shown promise in earlier trials, and the upcoming webinar is expected to provide clarity on the path to potential regulatory approval.
In addition to the Phase 3 AD trial, Annovis plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. This study will complement the company’s ongoing PD open-label study and its discussions regarding the initiation of a Parkinson’s disease dementia program. These initiatives highlight Annovis’s comprehensive approach to tackling multiple neurodegenerative conditions, which share common pathological mechanisms.
The webinar will also serve as a platform for Maccecchini to address the company’s strategic direction and the significance of its upcoming milestones. The announcement of the fully enrolled Phase 3 AD trial is particularly noteworthy, as it moves Annovis closer to a potential new treatment for Alzheimer’s disease, a condition affecting millions worldwide. The expected top-line data in 2027 could be a pivotal moment for the company and for patients awaiting new therapeutic options.
For investors, the webinar offers an opportunity to gain insights into Annovis’s clinical progress and regulatory timeline. The company’s focus on both AD and PD positions it in a growing market for neurodegenerative disease treatments, where there remains a high unmet need. Annovis’s approach of targeting multiple toxic proteins simultaneously could differentiate it from other therapies that focus on single targets.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is committed to developing treatments that address the underlying causes of neurodegeneration. More information about the company and its programs can be found at Annovis Bio. For the latest news and updates relating to ANVS, visit the company’s newsroom at Annovis Bio Newsroom.
